Generalized morphea induced by the COVID-19 vaccine in a patient with chronic urticaria


Published: 23 December 2022
Abstract Views: 1397
PDF: 345
HTML: 68
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Adverse events following vaccinations have been noted for centuries, but as of recently, discussions concerning these adverse effects have increased due to the COVID-19 pandemic and the consequent delivery of vaccinations. Through presenting new cases of such adverse events and reviewing the literature, we aim to facilitate the recognition of COVID-19 vaccine-induced autoimmune diseases that may occur in the years after the pandemic has been contained. We report on a case of biopsy-proven morphea after the COVID-19 vaccine, in which case the patient developed diffuse skin lesions all over her body. The patient was known to have chronic urticaria and received two doses of the Pfizer-BioNTech COVID-19 vaccines (BioNTech, Fosun Pharma, Pfizer, New York City, USA). The patient started to notice itchy lesions on her arms two months after taking her second dose of the vaccine. This is the first case reported of generalized morphea following COVID-19 vaccination with another autoimmune disease and represents the first case of generalized morphea reported in the Middle East.


Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: Current concepts. Clin Dermatol. 2018 Jul-Aug;36(4):475-486. doi: 10.1016/j.clindermatol.2018.04.005. Epub 2018 Apr 10. PMID: 30047431. DOI: https://doi.org/10.1016/j.clindermatol.2018.04.005

Antoñanzas J, Rodríguez-Garijo N, Estenaga Á, Morelló-Vicente A, España A, Aguado L. Generalized morphea following the COVID vaccine: A series of two patients and a bibliographic review. Dermatol Ther. 2022 Sep;35(9):e15709. doi: 10.1111/dth.15709. Epub 2022 Jul 20. PMID: 35811413; PMCID: PMC9349378. DOI: https://doi.org/10.1111/dth.15709

Penmetsa GK, Sapra A. Morphea. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 32644436.

Shakoei S, Kalantari Y, Nasimi M, Tootoonchi N, Ansari MS, Razavi Z, Etesami I. Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases. Dermatol Ther. 2022 Aug;35(8):e15651. doi: 10.1111/dth.15651. Epub 2022 Jul 4. PMID: 35716105; PMCID: PMC9349410. DOI: https://doi.org/10.1111/dth.15651

Paolino G, Campochiaro C, Di Nicola MR, Mercuri SR, Rizzo N, Dagna L, Rongioletti F, De Luca G. Generalized morphea after COVID-19 vaccines: a case series. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e680-e682. doi: 10.1111/jdv.18249. Epub 2022 May 31. PMID: 35604052; PMCID: PMC9348393. DOI: https://doi.org/10.1111/jdv.18249

Metin Z, Celepli P. A case of morphea following the COVID-19 mRNA vaccine: on the basis of viral spike proteins. Int J Dermatol. 2022 May;61(5):639-641. doi: 10.1111/ijd.16062. Epub 2022 Jan 24. PMID: 35073411. DOI: https://doi.org/10.1111/ijd.16062

Oh DAQ, Tee SI, Heng YK. Morphoea following COVID-19 vaccination. Clin Exp Dermatol. 2022 Jul 29:10.1111/ced.15349. doi: 10.1111/ced.15349. Epub ahead of print. PMID: 35906013; PMCID: PMC9353297.

Aryanian Z, Balighi K, Hatami P, Tootoonchi NM, Goodarzi A, Mohseni Afshar Z. Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection. Clin Case Rep. 2022 Apr 18;10(4):e05667. doi: 10.1002/ccr3.5667. PMID: 35449768; PMCID: PMC9014706. DOI: https://doi.org/10.1002/ccr3.5667

Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021 Apr;21(4):195-197. doi: 10.1038/s41577-021-00526-x. PMID: 33674759; PMCID: PMC7934118. DOI: https://doi.org/10.1038/s41577-021-00526-x

Sartori-Valinotti JC, Tollefson MM, Reed AM. Updates on morphea: role of vascular injury and advances in treatment. Autoimmune Dis. 2013;2013:467808. doi: 10.1155/2013/467808. Epub 2013 Nov 12. PMID: 24319593; PMCID: PMC3844232. DOI: https://doi.org/10.1155/2013/467808

Hend Alotaibi , Department of Dermatology, College of Medicine, King Saud University, Riyadh;

 

 

Alotaibi , H., Alsalhi, A., Albinhar, T., Alshathry, Y., & Barakeh, M. (2022). Generalized morphea induced by the COVID-19 vaccine in a patient with chronic urticaria. Dermatology Reports, 15(2). https://doi.org/10.4081/dr.2023.9632

Downloads

Download data is not yet available.

Citations